BACKGROUND: Pulse oximetry alone has been suggested to determine which patients on home mechanical ventilation (MV) require further investigation of nocturnal gas exchange. In patients with neuromuscular diseases, alveolar hypoventilation (AH) is rarely accompanied with ventilationperfusion ratio heterogeneity, and, therefore, oximetry may be less sensitive for detecting AH than in patients with lung disease. OBJECTIVE: To determine whether pulse oximetry (S pO 2 ) and transcutaneous carbon dioxide (P tcCO 2 ) during the same night were interchangeable or complementary for assessing home MV efficiency in patients with neuromuscular diseases. METHODS: Data were collected retrospectively from the charts of 58 patients with chronic neuromuscular respiratory failure receiving follow-up at a home MV unit. S pO 2 and P tcCO 2 were recorded during a 1-night hospital stay as part of standard patient care. We compared AH detection rates by P tcCO 2 , S pO 2 , and both. RESULTS: AH was detected based on P tcCO 2 alone in 24 (41%) patients, and based on S pO 2 alone with 3 different cutoffs in 3 (5%), 8 (14%), and 13 (22%) patients, respectively. Using both P tcCO 2 and S pO 2 showed AH in 25 (43%) patients. CONCLUSIONS: Pulse oximetry alone is not sufficient to exclude AH when assessing home MV efficiency in patients with neuromuscular diseases. Both P tcCO 2 and S pO 2 should be recorded overnight as the first-line investigation in this population.
Introduction
Home mechanical ventilation (MV) is used to diminish alveolar hypoventilation (AH), and is generally applied initially at night. 1 Studies have shown that simultaneous recording of transcutaneous carbon dioxide partial pressure (P tcCO 2 ) and pulse oximetry (S pO 2 ) is the best method for assessing the efficiency of nocturnal home MV in improving blood gas values [1] [2] [3] [4] [5] and detecting prolonged AH and short periods of sleep-related breathing disorders (leaks, asynchrony, and glottis closure). However, to save time and diminish costs, screening with nocturnal pulse oximetry alone, which is easier than recording P tcCO 2 , especially at home, has been suggested as a means of identifying those patients who require further nocturnal investigations. 6 -8 The criteria used to define AH differ according to the cause of respiratory failure and are more sensitive for restrictive than obstructive diseases. 1 In addition, restrictive defects due to neuromuscular diseases (NMDs) are usually characterized by higher baseline P aO 2 values than are obstructive defects. 9 Therefore, AH detection using S pO 2 alone may lack sensitivity in patients with NMDs.
The objective of the present study was to compare S pO 2 and P tcCO 2 values recorded during the same night in patients with NMDs, to determine whether these 2 parameters are interchangeable or complementary for assessing the efficiency of MV.
Methods
The study protocol was approved by the French Data Protection Authority (Commission Informatique et Libertés), in accordance with French legislation.
Study Patients
Data were collected retrospectively from the charts of patients with NMDs receiving follow-up at the home MV unit of the Raymond Poincaré Teaching Hospital, Garches, France. The patients had chronic restrictive respiratory failure and underwent a routine evaluation of the invasive or noninvasive MV protocol they used at home. This evaluation was done during a 1-night hospital stay, as part of standard patient care, between June 2009 and July 2011. Both S pO 2 and P tcCO 2 were recorded overnight. We did not include patients on oxygen therapy or having daytime P aO 2 values Ͻ 60 mm Hg.
Data Collection
The following were collected: anthropometric parameters; type of NMD; symptoms of sleep-disordered breathing or nocturnal hypoventilation (numerous awakenings, nocturnal agitation, diurnal asthenia, sleepiness); lung function test results (vital capacity, maximal inspiratory and expiratory static mouth pressures); time since MV initiation; time on MV per 24-hour cycle; ventilatory parameters; and interface.
P tcCO 2 and S pO 2 Measurements
Overnight continuous noninvasive P tcCO 2 and S pO 2 monitoring was achieved using a monitor (Digital Monitoring System, SenTec, Therwil, Switzerland) equipped with a noninvasive combined P tcCO 2 (Severinghaus-type electrode), S pO 2 , and heart rate sensor (V-Sign, SenTec, Therwil, Switzerland). Recording was started at the patient's usual bedtime and lasted 8 hours, which was the maximal possible recording duration with this device.
As recommended by the manufacturer, the electrode was calibrated in a docking station before each measurement, using a service gas (mixture of 8% CO 2 , 12% O 2 , and 80% N 2 ) (SenTec, Therwil, Switzerland), which took approximately 4 -11 min. The sensor membrane was changed every 14 days. The skin was cleansed thoroughly with isopropanol 70%, then dried. A small drop of sensor gel (SenTec, Therwil, Switzerland) was applied to the center of the sensor membrane surface, which was then secured to the ear lobe with a low-pressure ear clip and a tape in front of the ear. The electrode temperature was set at 42°C to increase blood flow, thereby improving skin permeability to gases and arterializing the capillaries in order to record P tcCO 2 values and subsequently to estimate P aCO 2 . P tcCO 2 monitoring began after 5-8 min (required for warming of the measurement site, complete local arterialization, and equilibration of CO 2 concentrations between the skin and sensor) and lasted 8 hours. In the event of P tcCO 2 signal interruption due to patient movements or passive body mobilization, the electrode was recalibrated and the sensor secured again to the earlobe. According to the manufacturer, measurement resolution was typically 0.8 mm Hg, with an in vitro drift estimated at Ͻ 1%/hour and a response time shorter than 80 s.
Overnight S pO 2 was recorded in the first patients using both pulse oximetry with a finger sensor (BlueNight, SleepInnov Technology, Moirans, France) and the pulse oximetry sensor incorporated in the combined P tcCO 2 , S pO 2 , and heart rate sensor described above. No significant differences were found between the values supplied by the 2 S pO 2 sensors, and, consequently, only the combined sensor was used in the remaining patients.
Daytime Blood Gas Measurement
According to routine clinical practice in the unit, daytime blood gas values were obtained in all patients receiving invasive MV, on the morning after the overnight recording. The blood sample was drawn at rest, in the sitting position. In addition, in patients on noninvasive MV, daytime blood gas values were measured in the afternoon on room air.
Data Analysis
Normal blood gas values were defined based on the normal values for our laboratory: pH 7.38 -7.42, P aO 2 90 -100 mm Hg, bicarbonate 24 -28 mmol/L, and base excess
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Current knowledge
Nocturnal ventilation in patients with neuromuscular disease is often indicated for reversal of alveolar hypoventilation. These patients are often monitored with oximetry for detection of gas exchange abnormalities.
What this paper contributes to our knowledge
Pulse oximetry alone cannot exclude alveolar hypoventilation when assessing home mechanical ventilation efficiency in patients with neuromuscular diseases. Both transcutaneously measured partial pressure of carbon dioxide (P tcCO 2 ) and S pO 2 should be recorded overnight as the first-line investigation. 0 Ϯ 2 mmol/L. Daytime hypercapnia was defined as P aCO 2 Ͼ 45 mm Hg. 1 Specifically designed software (V-Stats 3.00, SenTec, Therwil, Switzerland) was used to transfer and analyze stored nocturnal S pO 2 and P tcCO 2 data. Graphs and tables were established, and times spent above or below predefined P tcCO 2 or S pO 2 cutoffs were determined. We visually examined the graphs for each entire recording night to identify artifact-free periods. We then determined the artifact-free recording times; the maximal, minimal, and mean nocturnal P tcCO 2 and S pO 2 values; and the times spent with P tcCO 2 Ն 49 mm Hg and with S pO 2 Ͻ 90%.
Nocturnal AH was defined as abnormal P tcCO 2 or S pO 2 values. P tcCO 2 was considered abnormal when the maximal value was Ն 49 mm Hg. 10 Three different criteria were used to define abnormal S pO 2 , in separate analyses: a value Յ 88% for at least 5 consecutive minutes (criterion 1), 1 mean nocturnal S pO 2 Ͻ 90% or S pO 2 Ͻ 90% during Ն 10% of the total recording time (criterion 2), 6, 11 and mean nocturnal S pO 2 Ͻ 92% or S pO 2 Ͻ 92% during Ն 10% of the total recording time (criterion 3). 5 
Statistics
The data are described as median and IQR. We used the chi-square test to compare AH detection by S pO 2 alone and P tcCO 2 alone, to compare clinical characteritics between patients with and without nocturnal elevated P tcCO 2 values and to correlate presence of symptoms with nocturnal gas exchange abnormalities. The Mann-Whitney test was used to compare continuous variables between patients with and without nocturnal hypercapnia.
P values Ͻ .05 were considered significant. All analyses were performed using statistics software (Prism 5, GraphPad Software, San Diego, California).
Results
Population Characteristics
We identified 169 patients with nocturnal P tcCO 2 recordings performed at our home MV unit during the study period. Among them, 58 (34%) were home MV users. None of these 58 patients was on oxygen therapy. Table 1 shows the main characteristics of the study population.
Of the 58 study patients, 33 (57%) had severe respiratory muscle disease, with vital capacity values Ͻ 20% of predicted, and maximal inspiratory and expiratory static mouth pressure values Ͻ 30% of predicted in 41 (71%) patients and 43 (74%) patients, respectively. Forty-one (71%) patients used volume controlled ventilators. Body mass index was Ն 30 kg/m 2 in 3 patients (one each with kyphoscoliosis, Steinert myotony, and facioscapulohumeral muscular dystrophy). No patient had obstructive lung disease. The symptoms questionnaire was retrieved in 29 medical records among the 58 patients included: 18 patients showed symptoms of sleep-disordered breathing or nocturnal hypoventilation, and 11 patients were completely asymptomatic. 
Nocturnal S pO 2 and P tcCO 2 Monitoring
Abnormal peak P tcCO 2 values indicated AH in 24 (41%) of the 58 patients, and abnormal S pO 2 values in 3 (5%), 8 (14%), and 13 (22%) patients, with criteria 1, 2, and 3, respectively. The chi-square test comparing P tcCO 2 and S pO 2 showed highly significant differences using both S pO 2 criteria (P Ͻ .001 for criteria 1 and 2, and P ϭ .03 for criterion 3). Table 2 shows the results of combining P tcCO 2 and S pO 2 values for diagnosing AH. Among the 34 patients with normal P tcCO 2 values, 33 (97%, 57% of the overall study population) had normal S pO 2 values and one (3%, 2% of the overall study population) had abnormal S pO 2 values, according to criteria 1 or 2; this latter number increased to 4 (12%, 7% of the overall study population) patients with normal P tcCO 2 and abnormal S pO 2 considering criterion 3. Among the 24 patients with abnormal P tcCO 2 values, only 2 (8%) had abnormal S pO 2 values according to criterion 1, 7 (29%) according to criterion 2, and 15 (38%) according to criterion 3. Thus, the prevalence of high P tcCO 2 values among patients without hypoxemia was 40% (22/55) when criterion 1 was used, 34% (17/50) when criterion 2 was used, and 33% (15/45) when criterion 3 was used.
As reported in Table 3 , using both P tcCO 2 and S pO 2 (criterion 2) showed AH in 25 (43%) patients. The 2 tests combined increased the AH diagnosis rate by 29.3%, compared with S pO 2 alone (criterion 2), and by 1.7% compared with P tcCO 2 alone.
No correlation was found between symptoms of sleepdisordered breathing or nocturnal hypoventilation (18/29) and abnormalities of P tcCO 2 or S pO 2 with criteria 1, 2, or 3 (P ϭ .81, P ϭ .43, P ϭ .36, and P ϭ .14, respectively).
The 5 myotonic dystrophy patients were all ventilated using noninvasive MV. Four of them presented elevated nocturnal P tcCO 2 , but none of them presented oxygen desaturation according to criterion 1, whereas 3 of them presented oxygen desaturation according to criterion 2. The myotonic dystrophy patient without abnormal P tcCO 2 presented oxygen desaturation according to criterion 3 (S pO 2 Ͻ 92%).
Nocturnal P tcCO 2 Versus Morning Blood Gas Values
Among the 24 patients with nocturnal hypercapnia, 8 (33%) had high P aCO 2 values the next morning during objective wakefulness, whereas the remaining 16 patients (67%) had normal P aCO 2 values (P Ͻ .001). Moreover, patients with nocturnal hypercapnia had significantly higher values for the morning bicarbonate concentration 
Discussion
In our study of patients with NMDs, nocturnal pulse oximetry used to assess the efficiency of MV was not sufficient to exclude AH. About one third of the patients had AH manifesting as high P tcCO 2 values without substantial oxygen desaturation according to the usual S pO 2 criteria. 1, 6 On the other hand, oxygen desaturation without nocturnal hypercapnia was rare.
The usual criteria used to determine whether home MV is needed 1 were challenged recently by a study in which nocturnal hypercapnia predicted diurnal hypercapnia in patients with NMDs, and correcting nocturnal hypercapnia by MV prevented acute hypercapnia crises. 10 The cutoff used to define hypercapnia in this study was 49 mm Hg. 10 We also used this cutoff in our study, as no consensus exists about the best nocturnal P CO 2 criterion for assessing MV efficiency. Like Ward et al, 10 we did not use a minimal duration of P tcCO 2 Ն 49 mm Hg. In fact, 2 patients had a hypercapnia duration of Ͻ 5 min. Transferring these 2 patients in the non-hypercapnic group would not have changed the statistics significance and therefore the interpretation of the study. The cutoff used to define daytime hypercapnia is 45 mm Hg, 1 which takes into account the normal P CO 2 increase during sleep in adults. 12 For oxygen saturation we used the recommended cutoff for determining when MV is indicated, 1 considering that S pO 2 should not be Յ 88% for Ն 5 consecutive minutes when MV is efficient (S pO 2 criterion 1). According to a study of MV in patients with kyphoscoliosis, a reasonable goal is a mean nocturnal S pO 2 Ն 90%, with Ͻ 10% of the total recording time at S pO 2 Ͻ 90% after the correction of leaks. 6, 11 We used this possibly more sensitive cutoff for a separate analysis in our study (S pO 2 criterion 2). Finally, we also studied a third criterion for S pO 2 analysis (mean nocturnal S pO 2 Ն 92%, with Ͻ 10% of the total recording time at S pO 2 Ͻ 92%), 5 considering that the value of 90% may be too severe. With this latter criterion we increased detection of S pO 2 abnormalities, including patients with normal P tcCO 2 (see Table 2 ), suggesting another mechanism than AH for explaining oxygen desaturation.
With both S pO 2 cutoffs, P tcCO 2 was more sensitive than oximetry for detecting AH. Our criteria were similar to those used by Paiva et al, who compared S pO 2 and P tcCO 2 in a pediatric population with a variety of causes of respiratory failure. 5 This study provided the first evidence that hypercapnia was common during MV in patients without oxygen desaturation. Moreover, we did not find significant correlation between the clinical examination and nocturnal gas exchange abnormalities.
The sensitivity of S pO 2 for detecting AH is probably higher in patients with COPD. First, the diurnal hypercapnia cutoff used to determine when MV is required is higher in patients with COPD than in those with restrictive lung diseases. 1 Second, when COPD is so severe as to require MV, there is usually substantial heterogeneity in the ventilation-perfusion ratio. 9,13,14 Therefore, independently from AH severity, hypoxemia is common, and P aO 2 values may fall to levels at the steep portion of the oxyhemoglobin dissociation curve, where small P aO 2 decreases induced by worsening AH are associated with large drops in S pO 2 . 13, [15] [16] [17] For instance, a P aCO 2 increase of 5 mm Hg diminishes P aO 2 by about 6 mm Hg, which is largely sufficient to markedly decrease S pO 2 when P aO 2 is initially low. Thus, in patients with COPD, pulse oximetry alone may be accurate for detecting nocturnal respiratory anomalies, including AH. 6 An advantage of S pO 2 monitoring is the ability to detect brief decreases in MV efficiency, possibly explained by residual obstructive events, decreases in the central ventilatory command, or unintentional leaks. 6 Theoretically, these brief anomalies are not associated with P aCO 2 increases. In our population, however, nocturnal oxygen desaturation without hypercapnia was rare. Nevertheless, in practice, and given that currently available P tcCO 2 devices can accurately measure instantaneous S pO 2 , the issue is not choosing between S pO 2 and P tcCO 2 , but adding P tcCO 2 to S pO 2 .
The limitations of transcutaneous CO 2 monitors have been largely overcome in recent years. First, although electrode calibration before each recording remains necessary, membrane changes can be performed less frequently. Second, the lag time has decreased from 5 min on average 4 to approximately 2 min, 18 and the issue of sensor drift over the night has been solved by introducing a compensation that allows continuous recording for 8 hours without substantial signal drift 19 and without requiring 2 P aCO 2 determinations at the beginning and end of monitoring. 18 Third, several studies have shown good agreement between arterial and transcutaneous values, even during MV. 18, 19 Finally, P tcCO 2 -S pO 2 measurement devices are now sufficiently easy to use that they are suitable for home monitoring. 5 
Conclusions
In conclusion, given the design and performance improvements in transcutaneous CO 2 monitors, together with their ability to simultaneously monitor S pO 2 recording, and our results showing that P tcCO 2 is considerably more sensitive than S pO 2 for detecting MV inefficiency in patients with NMDs, we recommend the first-line use of nocturnal P tcCO 2 and S pO 2 monitoring rather than pulse oximetry alone for evaluating MV efficiency. If CO 2 monitoring is not available, a criterion usable in clinical practice for determining oximetry abnormalities should be adjusted individually with the knowledge of diurnal P aO 2 in order to appreciate the facility of S pO 2 decreasing during hypoventilation. In addition, morning blood gas determination should be preferred to evening blood gas determination for appreciating nocturnal MV effectiveness, as morning bicarbonate and base excess levels may accurately reflect nocturnal respiratory acidosis.
